ClinicalTrials.gg
CompletedNCT05150392Updated Dec 9, 2021

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

A Phase 3 interventional study of Investigational live attenuated varicella vaccine in Varicella, sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 2 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-09.

Sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Jul 2018, registered Nov 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,193
Allocation
Non-randomized
Ages
2 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Enrollment
7th of 36
1,193 · median 404
Started
2018
the only one that year
Phase 3
12 of 36
2 open now
Registered
27th of 36
by date
Lead sponsor
11 of 36
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 12 in phase 3, and was the 27th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 6 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

This is an open-labelled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of the single-dose primary immunization of live attenuated varicella vaccine on different time points ,and the safety and immunogenicity after the booster immunization

Read the detailed description

This study is an open-labelled phase Ⅲ clinical trial.The experimental vaccine manufactured by Sinovac(Dalian) Vaccine Technology Co., Ltd.A total of 1195 subjects who received vaccine in the phase Ⅲ lot-consistency clinical trial were be enrolled .All subjects except C0243 and C0556 were divided into 3 groups according to the order of study number.Subjects in 3 groups received a booster immunization of live attenuated varicella vaccines 1 year,2 years and 3 years after primary immunization,respectively.About 3.0ml of venous blood was collected from each enrolled subject at pre-booster immunization,30 days after booster immunization and the serum was separated for neutralizing antibody detection.The antibody levels were used to evaluate the immunity persistence and immunogenicity after booster immunization of live attenuated varicella vaccines .

03

Conditions studied

  • Varicella

Browse trials for

04

Who can participate

Ages eligible
2 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received one dose live attenuated varicella vaccine in the phase Ⅲ lot-consistency clinical trial;
  • Guardian(s) of the volunteer should be capable of understanding the written - consent form, and such form should be signed before the children being included into this study.

Exclusion criteria

Exclusion Criteria:

  • Received one dose live attenuated varicella vaccine at the end of the phase Ⅲ lot-consistency clinical trial;
  • According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,193 participants (actual)

Study arms

  • Experimental
    Booster immunization 1 year after primary immunization

    Subjects C0001-C0400 except C0243 received 1 dose of booster immunization 1 year after primary immunization.

    Biological: Investigational live attenuated varicella vaccine

  • Experimental
    Booster immunization 2 year after primary immunization

    Subjects C0401-C0800 except C0556 received 1 dose of booster immunization 2 years after primary immunization.

    Biological: Investigational live attenuated varicella vaccine

  • Experimental
    Booster immunization 3 year after primary immunization

    Subjects C0801-C1197 received 1 dose of booster immunization 3 years after primary immunization.

    Biological: Investigational live attenuated varicella vaccine

Interventions

  • The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection

06

What researchers measure

Primary outcomes

  1. Immunogenicity index-seroconversion rate of antibody

    seroconversion rates of antibody 1 year after primary immunization

    Time frame: 1 year after primary immunization

  2. Immunogenicity index-seroconversion rate of antibody

    seroconversion rates of antibody 2 years after primary immunization

    Time frame: 2 years after primary immunization

  3. Immunogenicity index-seroconversion rate of antibody

    seroconversion rates of antibody 3 years after primary immunization

    Time frame: 3 years after primary immunization

  4. Immunogenicity index-Seroconversion rate of antibody

    Seroconversion rate of the neutralizing antibody 30 days after booster immunization

    Time frame: 30 days after booster immunization

  5. Immunogenicity index-seropositivity rate of antibody

    Seropositivity rate of antibody 30 days after booster immunization

    Time frame: 30 days after booster immunization

Secondary outcomes

  1. Immunogenicity index-Seropositivity rate of antibody

    Seropositivity rate of antibody before booster immunization

    Time frame: Before the booster dose immunization

  2. Immunogenicity index-GMT of the antibody

    GMT of the antibody before booster immunization

    Time frame: Before the booster dose immunization

  3. Immunogenicity index- GMT of the antibody

    GMT of the antibody 30 days after booster immunization

    Time frame: 30 days after booster immunization

  4. Immunogenicity index- GMI of the antibody

    GMI of the antibody 30 days after booster immunization

    Time frame: 30 days after booster immunization

  5. Safety index-Incidence of solicited local or systemic AE

    Incidence of solicited local or systemic AE within 14 days after vaccination

    Time frame: within 14 days after vaccination

  6. Safety index-Incidence of local or systemic AE

    Incidence of local or systemic AE within 30 days after vaccination

    Time frame: within 30 days after vaccination

  7. Safety index-Incidence of SAE

    Incidence of SAE within 30 days after vaccination

    Time frame: within 30 days after vaccination

07

Study locations

1 site
  • Xiangfu County Center for Disease Control and Prevention
    Kaifeng, Henan 461700, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Aug 2018, 1 month.

Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's 1 month is below that.

Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Dec 9, 2021
StartActual
Jul 11, 2018
Primary completionActual
Aug 11, 2018
CompletionActual
Aug 14, 2020
Last update
Dec 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05150392
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Jul 11, 2018
Primary completion
Aug 11, 2018
Completion
Aug 14, 2020
Last update
Dec 9, 2021

Study contacts

Shengli Xia, Master
principal investigator · Henan Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion